Context Therapeutics Inc
CNTX0.680USD
-0.030-4.23%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
61.00MMarket Cap
LossP/E TTM
More Details of Context Therapeutics Inc Company
Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is building an advanced portfolio of clinical-stage T cell engaging bispecific therapeutics, including CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody, and CT-95, a potential first-in-class mesothelin x CD3 bispecific antibody. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window. The Company’s CT-95 is being developed as a therapy for advanced cancers associated with mesothelin (MSLN) expression.
Company Info
Ticker SymbolCNTX
Company nameContext Therapeutics Inc
IPO dateOct 20, 2021
CEOMr. Martin Lehr
Number of employees12
Security typeOrdinary Share
Fiscal year-endOct 20
Address2001 Market Street
CityPHILADELPHIA
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code19103
Phone12672257416
Websitehttps://www.contexttherapeutics.com/
Ticker SymbolCNTX
IPO dateOct 20, 2021
CEOMr. Martin Lehr
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Dr. Karen Chagin
Dr. Karen Chagin
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andy Pasternak
Mr. Andy Pasternak
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jennifer Minai-Azary
Ms. Jennifer Minai-Azary
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Karen L. Smith
Dr. Karen L. Smith
Independent Director
Independent Director
--
--
Mr. Alex Levit
Mr. Alex Levit
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Dr. Philip Kantoff, M.D.
Dr. Philip Kantoff, M.D.
Independent Director
Independent Director
--
--
Ms. Jennifer Evans Stacey, Esq.
Ms. Jennifer Evans Stacey, Esq.
Independent Director
Independent Director
--
--
Mr. Martin Lehr
Mr. Martin Lehr
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Linda West
Ms. Linda West
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Luke Walker, M.D.
Dr. Luke Walker, M.D.
Independent Director
Independent Director
--
--
Dr. Karen Chagin
Dr. Karen Chagin
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Andy Pasternak
Mr. Andy Pasternak
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Jennifer Minai-Azary
Ms. Jennifer Minai-Azary
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
Dr. Karen L. Smith
Dr. Karen L. Smith
Independent Director
Independent Director
--
--
Mr. Alex Levit
Mr. Alex Levit
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Thu, May 15
Updated: Thu, May 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
MPM BioImpact LLC
16.39%
Avidity Partners Management LP
8.34%
Nextech Invest, Ltd.
8.27%
Deep Track Capital LP
8.27%
Blue Owl Capital Holdings LP
8.21%
Other
50.52%
Shareholders
Shareholders
Proportion
MPM BioImpact LLC
16.39%
Avidity Partners Management LP
8.34%
Nextech Invest, Ltd.
8.27%
Deep Track Capital LP
8.27%
Blue Owl Capital Holdings LP
8.21%
Other
50.52%
Shareholder Types
Shareholders
Proportion
Hedge Fund
32.54%
Investment Advisor/Hedge Fund
28.40%
Investment Advisor
18.95%
Individual Investor
1.28%
Pension Fund
0.04%
Venture Capital
0.02%
Other
18.79%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
83
72.85M
81.21%
-6.27M
2025Q1
84
72.79M
81.15%
-6.34M
2024Q4
82
74.13M
98.85%
+11.14M
2024Q3
78
59.00M
83.49%
-2.98M
2024Q2
70
60.36M
95.58%
+23.56M
2024Q1
55
7.26M
44.20%
+845.56K
2023Q4
57
5.89M
35.58%
-393.75K
2023Q3
59
4.91M
29.47%
-988.92K
2023Q2
57
4.57M
27.35%
-530.46K
2023Q1
53
3.62M
22.67%
-2.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
MPM BioImpact LLC
14.71M
16.39%
--
--
Mar 31, 2025
Avidity Partners Management LP
7.48M
8.34%
--
--
Mar 31, 2025
Nextech Invest, Ltd.
7.42M
8.27%
--
--
Mar 31, 2025
Deep Track Capital LP
7.42M
8.27%
--
--
Mar 31, 2025
Blue Owl Capital Holdings LP
7.37M
8.21%
+1.01M
+15.89%
Mar 31, 2025
Great Point Partners, LLC
4.68M
5.22%
--
--
Mar 31, 2025
Franklin Advisers, Inc.
4.00M
4.46%
--
--
Mar 31, 2025
The Vanguard Group, Inc.
3.25M
3.63%
-2.00K
-0.06%
Mar 31, 2025
Blackstone Alternative Asset Management, L.P.
2.44M
2.72%
--
--
Mar 31, 2025
Nantahala Capital Management, LLC
1.94M
2.16%
--
--
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
